In 125 patients with advanced HER2-negative oesophagogastric adenocarcinoma stable or responding after platinum chemotherapy, maintenance rucaparib did not significantly improve PFS vs surveillance (median 4.2 vs 2.8 months; HR 0.70, P=0.031 vs 0.025 threshold); OS no different.
RCTn = 125
Gordon et al. Maintenance rucaparib after first-line platinum-based chemotherapy in HER2-negative advanced oesophagogastric adenocarcinoma: results from the PLATFORM study